skip to Main Content
pancreatic cancer researcher Wungki Park, M.D.

Claudin May Be the Next Big Target in Pancreatic Cancer Treatment

While immunotherapy and other targeted treatments involving monoclonal antibodies have been successful in other cancers, pancreatic cancer has been notoriously tough to target because of a lack of suitable cell surface targets to which the antibodies can bind. But a new target has been identified, and researchers are hopeful that an investigational drug that homes…

Back To Top